ACER3 and cancer: Furthermore, the inhibitor assay exhibits a possibility to develop direct and specific inhibitors of ACER3 and its related paralogs, ACER1 and ACER2, for treatments of diseases associated with dysregulation of the metabolism of ceramides and other sphingolipids, such as cancers, diabetes mellitus, cardiovascular diseases, neurodegenerative diseases, and skin diseases [5, 6, 21, 22].